偏瘫性肩痛患者腋囊的MRI观测及临床意义

目的通过MRI技术观察偏瘫患者肩疼痛腋囊形态变化,为影像诊断提供依据。方法对47例偏瘫性肩疼痛患者(疼痛组)和47例正常肩部(对照组),运用MRI技术对肩关节腋囊进行测量,观察腋囊下肱盂韧带信号。结果偏瘫性肩疼痛的腋囊厚度(4.1±1.45)mm,高于对照组。腋囊腔高度(8.70±1.80)mm,腋囊腔宽度(4.31±0.56)mm,小于对照组。偏瘫性肩痛下肱盂韧带呈高信号出现率达21%,腋囊厚度与VAS呈正相关,与肩关节外展外旋呈负相关。结论脑中风中后期肩周炎是引起偏瘫性肩疼痛患者的常见原因,腋囊厚度是限制肩关节活动度的重要因素。     

12例开放性腋动脉损伤的诊治

目的探讨开放性腋动脉损伤的诊治体会。方法1996年-2002年，共诊治12例开放性腋动脉损伤的患者，从受伤到入院时间为3～14h，入院时均处于不同程度的休克状态，桡动脉搏动减弱或消失。在积极抗休克治疗的同时，急诊进行清创、血管神经探查和修复术。其中行腋动脉修补5例，腋动脉直接吻合6例，自体静脉移植修复1例。结果伤后8h内腋动脉再通8例，8～16h内腋动脉再通4例，无病例发生截肢或死亡。术后伤口均Ⅰ期愈合，桡动脉搏动良好。结论对开放性腋动脉损伤早期诊断和及时手术探查是控制休克、获取良好疗效的关键。     

Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer

BACKGROUND: Since the advent of cisplatin-based chemotherapy, the majority of metastatic testicular cancers can be cured by chemotherapy followed by retroperitoneal lymph node dissection (RPLND). However, postchemotherapy RPLND confers no therapeutic benefit if the residual mass contains no viable cells. Therefore, to determine which parameters predict a patient's likelihood of having only necrosis in the residual mass, we retrospectively analyzed clinical parameters of patients who underwent postchemotherapy RPLND. METHODS: Data from 27 patients with metastatic testicular cancer were analyzed. The histology of the primary tumor was seminoma in 11 cases and non-seminoma in 16 cases. All of the patients with non-seminoma showed a normalization of tumor markers after chemotherapy. Analysis of clinical parameters included data for the initial histology, pretreatment tumor marker levels, postchemotherapy retroperitoneal mass size, and the histology of the dissected RPLNs. RESULTS: Histological examination of dissected RPLNs showed residual tumor in 27% of seminoma patients and 38% of non-seminoma patients. In seminoma patients, no viable cells were found in all six patients with pretreatment lactate dehydrogenase (LDH) levels below 7.5 times the upper limit of normal, or in all five of the patients with postchemotherapy RPLNs less than 2.5 cm. In non-seminoma patients, no viable cells were found in nine of 10 patients with pretreatment alpha-fetoprotein (AFP) levels less than 2700 ng/mL, or in eight of nine patients with residual mass less than 2.5 cm. CONCLUSIONS: Both postchemotherapy RPLN mass size and pretreatment tumor marker levels are possible predictors for necrosis of the residual mass in testicular cancer patients.     

腹股沟浅淋巴结移植的应用解剖

本文在32侧成人尸体上,对腹股沟浅淋巴结的形态及血供进行了观察和测量。腹股沟部上外区淋巴结有恒定的旋髂浅血管供应。动脉外径平均约1.5mm,干长21.8mm,营养2～6个淋巴结、该区是吻合血管移植淋巴结的首选供区。     

18F-FDG PET/CT对非小细胞肺癌区域淋巴结诊断的假阴性与假阳性研究

目的探讨18^F-FDG PET／CT在检测非小细胞肺癌（NSCLC）区域淋巴结中出现假阴性和假阳性的因素。方法随机选择手术治疗的NSCLC患者48例，术前1周内行18^F—FDG PET／CT检查，同期行CT增强扫描，术后根据病理检查结果分析PET／CT诊断NSCLC区域淋巴结转移的假阴性与假阳性因素。结果48例患者共切除区域淋巴结313枚，转移淋巴结51枚，PET／CT结果7枚假阴性。8枚假阳性，阳性预测值和阴性预测值分别为85％，97％，高于CT（57％，94％；P=0．002，0．045）。3枚假阴性淋巴结内的癌灶较小；2枚淋巴结短径约为0．4mm，小于PET／CT的空间分辨率；2枚紧邻原发灶的淋巴结，图像无法区分而视为原发灶。8枚假阳性淋巴结为患者在原发病灶基础上并发不同程度的肺部疾病和淋巴结炎症，使其糖代谢率增高。结论假阳性出于（1）淋巴结的短径小于PET／CT的空间分辨率；（2）淋巴结内的小癌灶糖代谢率较低；（3）紧邻原发灶的淋巴结与原发灶无法区分。原发肿瘤合并肺部疾病是导致PET／CT出现假阳性的重要原因。     

逆转录-聚合酶链反应检测胃癌淋巴结微转移

目的 检测胃癌常规病理检查阴性的淋巴结微转移的发生及与其它临床参考指标的关系。方法 利用逆转录－聚合酶链反应（RT－PCR）方法检测68枚胃癌胃周淋巴结癌胚抗原（CEA）mRNA基因表达，同时比较RT－PCR与免疫组化（IHC）方法的检测敏感性。结果 CEAmRNA RT－PCR是一种很敏感的方法，可以检测1／10^6个转移的癌细胞；检测19例胃癌患者取材的68枚胃周淋巴结，IHC阳性率28％（19／68），RT－PCR阳性率57％（39－68），两组之间差异有非常显著性意义（P＜0.01）；RT－PCR阳性率与胃部临床参考指标密切相关，且随着病期进展而增大。结论 CEA mRNA RT-PCR是比免疫组化更敏感的方法，可以预测胃癌淋巴结微转移，能够有效地避免已有微小转移的患者被漏诊。     

食管腺癌淋巴结转移与肿瘤侵及食管壁深度的关系

目的 对腺癌侵及食管壁深度与淋巴结转移的关系以及淋巴结转移对预后的影响进行分析研究.方法 澳大利亚弗林德斯大学医学中心自1985年～2003年,手术治疗食管腺癌121例.其中男101例,女20例.年龄36～80岁,平均62岁.本组手术切除率为96.7%（117/121例）.手术清扫淋巴结的数目每例为2～30个,平均8个.无淋巴结转移59例（48.8%）、有淋巴结转移62例（51.2%）.本组病例全部得到随访.结果 当肿瘤位于黏膜层或黏膜下层（T1）时,淋巴结转移的发生率为22.2%（10/45例）、平均淋巴结转移的个数为0.3个、＞4个淋巴结转移的比例为0（0/45例）;当肿瘤侵及食管周围组织（T4）时,淋巴结转移的发生率为85.7%（6/7例）、平均淋巴结转移的个数为5.1个、＞4个淋巴结转移的比例为71.4%（5/7例）,P＜0.05.无淋巴结转移组的5年生存率为52.9%、1～4个淋巴结转移组的5年生存率为11.5%、＞4个淋巴结转移组的5年生存率为0,P＜0.01.结论 肿瘤对食管壁侵及深度和淋巴结转移的发生率及淋巴结转移的数量之间存在正相关性.随着肿瘤对食管壁侵及深度的增加,淋巴结转移的发生率、平均淋巴结转移的数量和＞4个淋巴结转移的比例均增加.有无淋巴结转移和淋巴结转移的数量是影响远期生存率的一个重要因素.     

Surgical results of performing R4 gastrectomy for gastric cancer located in the upper third of the stomach

Because gastric cancers located in the upper third of the stomach are difficult to detect at an early stage, the surgical results remain poor. We performed R4 gastrectomy as a radical procedure for 25 patients, involving complete resection of the latero-aortic and interaorticovenous lymph modes above and below the left renal vein, in combination with the ordinary R2 or R3 gastrectomy (the R4 group). These patients were compared with 156 others who underwent R2 gastrectomy alone (the R2 group). There were no significant differences in operation time, blood loss, or the incidence of complications between the two groups; however, when the survival rates of the patients with tumors invading beyond the subserosa were compared, the 5-year survival rate was found to be significantly higher in the R4 group than in the R2 group. Furthermore, in patients with para-aortic nodal involvement, a significant survival advantage was observed in the R4 group, as compared with the R2 group. These results suggest that the R4 gastrectomy is a rational approach for patients with advanced gastric cancer located in the upper third of the stomach.